

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

## **VOLUNTARY ANNOUNCEMENT**

### **BUSINESS UPDATE: THIRD-PARTY PETITION FILED AGAINST THE COMPANY’S U.S. PATENT**

This announcement is made by Ascletis Pharma Inc. (the “**Company**” or “**Ascletis**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that it has become aware of a petition for Post Grant Review (the “**Petition**”) filed with the United States Patent and Trademark Office (“**USPTO**”) by Conjupro Biotherapeutics, Inc., a subsidiary of CSPC Pharmaceutical Group Limited (“**CSPC**”, a company listed on The Stock Exchange of Hong Kong Limited with stock code: 1093), on June 24, 2025. The Petition challenged the validity of claims 1-9, 12-17, and 21-25 of the granted U.S. patent No. 12,234,236 owned by Ascletis Pharma (China) Co., Limited, a subsidiary of the Company (the “**Patent**”). As of the date of this announcement, the Petition remains under review by the USPTO.

The molecular structure of Compound 1 covered by Ascletis’ granted Patent is identical to that of Compound 10 in CSPC’s pending patent application (Application No.: PCT/CN2024/140920; Applicant: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.). However, Ascletis had filed its patent application with the USPTO approximately three (3) months prior to CSPC’s application, the latter of which remains pending as of the date of this announcement. While the Company cannot speculate on CSPC’s motivations for filing the Petition, it is noteworthy that in late March 2025, the Company’s management received and subsequently declined an unsolicited global licensing request from CSPC regarding Compound 1, a GLP-1R agonist, covered by the Patent.

The Patent was developed with Ascletis’ proprietary technologies and is currently being utilized in the research and development of the Company’s drug candidate ASC30. The Company’s compounds including Compound 1 and ASC30 are protected by various patents, including the aforementioned Patent. The Patent was granted to Ascletis Pharma (China) Co., Limited by the USPTO on February 25, 2025 based on its novelty and non-obviousness over the prior art.

The Company maintains full confidence in the validity of the Patent and will take all necessary legal actions to defend its intellectual property rights should the Petition proceed further.

As the Petition remains under review of the USPTO, its potential impact on the Group cannot be determined at this stage. The Company will closely monitor the Petition's progress and assess its impact, while its current business operations continue unaffected.

The Company will make further announcement(s) to update shareholders and potential investors of the Company on material developments regarding the Petition as and when appropriate in compliance with the Listing Rules.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Ascletis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hong Kong  
June 30, 2025

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*